- Stocks
- Pharma & Healthcare
- Dr. Agarwal's Health Care
Dr. Agarwal's Health Care share price
NSE: AGARWALEYEPharma & Healthcare
Dr. Agarwal's Health Care at a glance
Dr. Agarwal's Health Care (NSE: AGARWALEYE) closed at ₹459.10 on 22 Oct 2026, down 1.51% on the day. With a market capitalisation of ₹14,852 Cr, it ranks 426th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.
At its last close the stock traded at 100× trailing earnings, against a return on equity of 6.6% in FY26. Over the past year the share price has fallen 10.7%. Its 52-week range is ₹401.00 (30 Mar 2026) to ₹567.75 (11 Aug 2026); the last close is 19.1% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹614 Cr (+26.0% year on year) and net profit ₹55 Cr (+44.6%), on a consolidated basis. Promoters held 32.34% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹14,852 CrRank 426 on NSE
- P/E (trailing)
- 100×
- Price to book
- 6.35×FY26
- EPS (TTM)
- ₹4.69to Q1 FY27
- ROE
- 6.6%FY26
- ROCE
- 9.7%FY26
- Debt to equity
- 0.08FY26
- Net profit margin
- 3.1%FY26
- Book value / share
- ₹63.93FY26
- 52-week high
- ₹567.7511 Aug 2026
- 52-week low
- ₹401.0030 Mar 2026
- 1-year return
- −10.7%
- RSI (14-day)
- 38.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.51% | −1.7% | −6.2% | −3.1% | −10.7% |
Dr. Agarwal's Health Care quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹417 Cr | ₹431 Cr | ₹460 Cr | ₹487 Cr | ₹499 Cr | ₹530 Cr | ₹564 Cr | ₹614 Cr |
| Revenue YoY | — | +29.5% | +33.6% | +20.8% | +19.7% | +23.0% | +22.6% | +26.0% |
| Net profit | ₹21 Cr | ₹28 Cr | ₹43 Cr | ₹38 Cr | ₹36 Cr | ₹44 Cr | ₹50 Cr | ₹55 Cr |
| Net profit YoY | — | +25.0% | +3.0% | +108.9% | +71.0% | +54.5% | +17.4% | +44.6% |
| Net margin | 5.1% | 6.6% | 9.2% | 7.8% | 7.3% | 8.2% | 8.9% | 9.0% |
| EPS | ₹0.57 | ₹0.73 | ₹1.04 | ₹0.95 | ₹0.94 | ₹1.07 | ₹1.25 | ₹1.43 |
Dr. Agarwal's Health Care financials
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹696 Cr | ₹1,018 Cr | ₹1,332 Cr | ₹1,711 Cr | ₹2,080 Cr |
| Operating profit | ₹57 Cr | ₹84 Cr | ₹141 Cr | ₹163 Cr | ₹247 Cr |
| Net profit | ₹43 Cr | ₹103 Cr | ₹95 Cr | ₹110 Cr | ₹168 Cr |
| EPS (₹) | ₹2.00 | ₹4.00 | ₹3.00 | ₹3.00 | ₹4.00 |
| Cash from operations | ₹164 Cr | ₹233 Cr | ₹346 Cr | ₹360 Cr | ₹519 Cr |
| Total debt | ₹254 Cr | ₹306 Cr | ₹310 Cr | ₹157 Cr | ₹133 Cr |
| Shareholders' equity | ₹212 Cr | ₹630 Cr | ₹1,339 Cr | ₹1,867 Cr | ₹2,025 Cr |
Dr. Agarwal's Health Care shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 32.45% | 32.42% | 32.42% | 32.39% | 32.36% | 32.34% |
| Foreign institutions | 60.62% | 59.26% | 58.13% | 58.06% | 57.94% | 57.96% |
| Domestic institutions | 5.21% | 6.44% | 7.92% | 7.78% | 7.83% | 7.72% |
| Non-institutions | 1.72% | 1.88% | 1.52% | 1.77% | 1.87% | 1.98% |
Dr. Agarwal's Health Care vs peers
The listed Pharma & Healthcare companies nearest to Dr. Agarwal's Health Care by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ERISEris Lifesciences | ₹1,143.60 | +0.76% | −27.9% | ₹15,537 Cr | 25.3 | 15.9% |
| APLLTDAlembic Pharmaceuticals | ₹785.00 | −0.41% | −14.0% | ₹15,357 Cr | 22.9 | 11.2% |
| ASTRAZENAstraZeneca Pharma India | ₹6,056.00 | −0.38% | −33.5% | ₹15,252 Cr | 80.9 | 15.0% |
| SYNGENESyngene International | ₹370.75 | −1.12% | −40.8% | ₹15,037 Cr | 47 | 6.5% |
| AGARWALEYEDr. Agarwal's Health Care | ₹459.10 | −1.51% | −10.7% | ₹14,852 Cr | 100 | 6.6% |
| JUBLPHARMAJubilant Pharmova | ₹930.80 | −0.02% | −13.4% | ₹14,848 Cr | 37.1 | 13.4% |
| POLYMEDPoly Medicure | ₹1,479.10 | +1.31% | −20.5% | ₹14,686 Cr | 46.7 | 10.4% |
Ask anything about Dr. Agarwal's Health Care
Pivot answers on the live chart with evidence you can check, and tests strategies against AGARWALEYE's own history. Try: “Why has AGARWALEYE moved over the last three months?” · “Backtest a 50-day moving-average crossover on AGARWALEYE over five years” · “Compare AGARWALEYE with ERIS on margins and valuation”
Frequently asked questions about Dr. Agarwal's Health Care
What is the share price of Dr. Agarwal's Health Care today?
Dr. Agarwal's Health Care (NSE: AGARWALEYE) last closed at ₹459.10 on 22 Oct 2026. Its 52-week high is ₹567.75 and its 52-week low is ₹401.00.
What is the market cap of Dr. Agarwal's Health Care?
Dr. Agarwal's Health Care's market capitalisation is ₹14,852 Cr (₹14,852 Cr) at the 22 Oct 2026 close, ranking 426th among the NSE companies Pivot tracks.
What is the P/E ratio of Dr. Agarwal's Health Care?
Dr. Agarwal's Health Care trades at a trailing P/E of 100. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.7.
What is the ROE and ROCE of Dr. Agarwal's Health Care?
Return on equity was 6.6% in FY26 and return on capital employed was 9.7% in FY26 (consolidated figures).
Is Dr. Agarwal's Health Care a debt-free company?
No. Dr. Agarwal's Health Care's debt-to-equity ratio was 0.08 in FY26, with total debt of ₹133 Cr.
What were Dr. Agarwal's Health Care's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Dr. Agarwal's Health Care reported revenue of ₹614 Cr, +26.0% year on year, and net profit of ₹55 Cr, +44.6% year on year.
How has Dr. Agarwal's Health Care stock performed over the last year?
Dr. Agarwal's Health Care's share price has fallen 10.7% over the past year, −3.1% over three months and −6.2% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Dr. Agarwal's Health Care?
As of 30 Jun 2026: promoters 32.34%, foreign institutions 57.96%, domestic institutions 7.72%, non-institutions 1.98%.
Who are Dr. Agarwal's Health Care's competitors?
The listed Pharma & Healthcare companies closest to Dr. Agarwal's Health Care by market cap are Eris Lifesciences, Alembic Pharmaceuticals, AstraZeneca Pharma India, Syngene International, Jubilant Pharmova and Poly Medicure.
Is Dr. Agarwal's Health Care a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Dr. Agarwal's Health Care's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AGARWALEYE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with D · all NSE stocks · this page as text